Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer's disease

Autor: Ross Jeggo, David Spanswick, Eugene O'Hare, Edmund Nerou, Philip Palmer, Bridgeen McMahon, J. Mark Treherne, Hozefa Amijee, Eun-Mee Kim, David I.C. Scopes

Publikováno v: The International Journal of Neuropsychopharmacology. 17:117-126

Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer's disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff252bbaf61bb05c58979e4881b9c113
https://doi.org/10.1017/s1461145713000886

Novel Anti-Inflammatory Compound SEN1176 Alleviates Behavioral Deficits Induced Following Bilateral Intrahippocampal Injection of Aggregated Amyloid-β1-42

Autor: J.M. Treherne, E Kim, J. Monaghan, Philip Palmer, Eugene O'Hare, David I.C. Scopes, Hozefa Amijee

Publikováno v: Journal of Alzheimer's Disease. 25:219-229

Behavioral effects of a novel anti-inflammatory SEN1176 were investigated. This pyrrolo[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine suppresses amyloid-β (Aβ)1-42-induced macrophage production of nitric oxide, TNF-α, IL-1β, and IL-6 in a dose-dependent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::111ee9c0ca4835d3e464d4fdf3fd091b
https://doi.org/10.3233/jad-2011-100044

The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease

Autor: Hozefa Amijee, David I.C. Scopes

Publikováno v: Journal of Alzheimer's Disease. 17:33-47

Amyloid-beta (Abeta) peptide is one of the most promising targets for the development of new therapies for Alzheimer's disease (AD). A growing body of evidence suggests a key pathogenic role for soluble oligomers of Abeta, and therapeutics which bloc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17c9ef5d55ac10b2c57ac64bc58d263b
https://doi.org/10.3233/jad-2009-1044

Orally bioavailable small molecule drug protects memory in Alzheimer's disease models

Autor: Bridgeen McMahon, Philip Palmer, Andrew D. Whyment, Edmund Nerou, T Mark Treherne, Ross Jeggo, David I.C. Scopes, Hozefa Amijee, Martyn Jones, Eugene O'Hare, Eun-Mee Kim, David Spanswick

Publikováno v: O'Hare, E, Scopes, D I C, Kim, E-M, Palmer, P, Jones, M, Whyment, A D, Spanswick, D, Amijee, H, Nerou, E, McMahon, B, Treherne, J M & Jeggo, R 2013, ' Orally bioavailable small molecule drug protects memory in Alzheimer's disease models ', Neurobiology of Aging, vol. 34, no. 4, pp. 1116-1125 . https://doi.org/10.1016/j.neurobiolaging.2012.10.016

Oligomers of beta-amyloid (Aß) are implicated in the early memory impairment seen in Alzheimer's disease before to the onset of discernable neurodegeneration. Here, the capacity of a novel orally bioavailable, central nervous system-penetrating smal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930a79248a30fa93cf450b4e15d39877
https://pubmed.ncbi.nlm.nih.gov/23164690

Novel anti-inflammatory compound SEN1176 alleviates behavioral deficits induced following bilateral intrahippocampal injection of aggregated amyloid-β₁₋₄₂

Autor: Eugene, O'Hare, David I C, Scopes, J Mark, Treherne, John, Monaghan, Philip M, Palmer, Hozefa, Amijee, Eun-Mee, Kim

Publikováno v: Journal of Alzheimer's disease : JAD. 25(2)

Behavioral effects of a novel anti-inflammatory SEN1176 were investigated. This pyrrolo[3,2-e][1,2,4]triazolo[1,5-a]pyrimidine suppresses amyloid-β (Aβ)1-42-induced macrophage production of nitric oxide, TNF-α, IL-1β, and IL-6 in a dose-dependent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d4c58d4402cbf0e712cf33bdec3fafcb
https://pubmed.ncbi.nlm.nih.gov/21654060